MedTrace Logo

A Study of ONO-1110 in Patients With Major Depressive Disorder

NCT06792136 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-20

No results posted yet for this study

Summary

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Major Depressive Disorder

Conditions

  • Major Depressive Disorder (MDD

Interventions

DRUG

ONO-1110

ONO-1110 tablets once a day

DRUG

Placebo

Placebo tablets once daily

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Project Leader · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06792136 on ClinicalTrials.gov